Literature DB >> 30903617

Palliation of malignant ascites.

Caitlin Hodge1, Brian D Badgwell2.   

Abstract

Malignant ascites (MA) carries a poor prognosis. It can have a significant impact on quality of life (QOL), with increasing abdominal distention, pain, and dyspnea. Diuretics typically do not work well for MA. Paracentesis is effective in providing temporary symptom relief but requires frequent repeat procedures. Options for durable symptom management include indwelling catheters, peritoneal ports, peritoneovenous shunts, intraperitoneal (i.p.) catumaxomab, and hyperthermic i.p. chemotherapy. These interventions do not necessarily improve overall survival but may improve QOL.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  catumaxomab; hyperthermic intraperitoneal chemotherapy; paracentesis; peritoneal carcinomatosis

Mesh:

Year:  2019        PMID: 30903617     DOI: 10.1002/jso.25453

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  12 in total

1.  Post-PRRT scans: which scans to make and what to look for.

Authors:  Else A Aalbersberg; Daphne M V de Vries-Huizing; Margot E T Tesselaar; Marcel P M Stokkel; Michelle W J Versleijen
Journal:  Cancer Imaging       Date:  2022-06-17       Impact factor: 5.605

Review 2.  The untapped potential of ascites in ovarian cancer research and treatment.

Authors:  Caroline Elizabeth Ford; Bonnita Werner; Neville Frederick Hacker; Kristina Warton
Journal:  Br J Cancer       Date:  2020-05-08       Impact factor: 7.640

3.  Oncolytic adenovirus inhibits malignant ascites of advanced ovarian cancer by reprogramming the ascitic immune microenvironment.

Authors:  Gang Shi; Pengyi Shi; Yan Yu; Jia Xu; Jinhu Ma; Yong Zhang; Zhexu Dong; Lanlin Shen; Lei Dai; Lin Cheng; Ping Cheng; Hongxin Deng
Journal:  Mol Ther Oncolytics       Date:  2021-11-11       Impact factor: 7.200

4.  Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.

Authors:  Naosuke Yokomichi; Kengo Imai; Masaki Sakamoto; Masashi Horiki; Toshihiro Yamauchi; Satoru Miwa; Satoshi Inoue; Yu Uneno; Hidekazu Suzuki; Toru Wada; Yuri Ichikawa; Tatsuya Morita
Journal:  BMC Cancer       Date:  2022-02-28       Impact factor: 4.430

5.  Localized Intra-Cavitary Therapy to Drive Systemic Anti-Tumor Immunity.

Authors:  Vera S Donnenberg; Patrick L Wagner; James D Luketich; David L Bartlett; Albert D Donnenberg
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

6.  Intraperitoneal oncolytic virotherapy for patients with malignant ascites: Characterization of clinical efficacy and antitumor immune response.

Authors:  Yalei Zhang; Ling Qian; Kun Chen; Sijia Gu; Jia Wang; Zhiqiang Meng; Ye Li; Peng Wang
Journal:  Mol Ther Oncolytics       Date:  2022-03-15       Impact factor: 7.200

7.  B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study.

Authors:  Shakeel Modak; Pat Zanzonico; Milan Grkovski; Emily K Slotkin; Jorge A Carrasquillo; Serge K Lyashchenko; Jason S Lewis; Irene Y Cheung; Todd Heaton; Michael P LaQuaglia; Nai-Kong V Cheung; Neeta Pandit-Taskar
Journal:  J Clin Oncol       Date:  2020-10-29       Impact factor: 44.544

8.  Management of drainage for malignant ascites in gynaecological cancer.

Authors:  Chumnan Kietpeerakool; Siwanon Rattanakanokchai; Nampet Jampathong; Jatupol Srisomboon; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2019-12-11

9.  Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites.

Authors:  Jie Jiao; Chengzhen Li; Guanying Yu; Lei Zhang; Xiaoyan Shi; Jingdu Yan; Houjun Zhang; Peiming Guo
Journal:  World J Surg Oncol       Date:  2020-07-22       Impact factor: 2.754

10.  Lentinan-functionalized Selenium Nanoparticles target Tumor Cell Mitochondria via TLR4/TRAF3/MFN1 pathway.

Authors:  Hui-Juan Liu; Yuan Qin; Zi-Han Zhao; Yang Zhang; Jia-Huan Yang; Deng-Hui Zhai; Fang Cui; Ce Luo; Man-Xi Lu; Piao-Piao Liu; Heng-Wei Xu; Kun Li; Bo Sun; Shuang Chen; Hong-Gang Zhou; Cheng Yang; Tao Sun
Journal:  Theranostics       Date:  2020-07-11       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.